Esophageal Carcinomas and Carcinomas of the Gastroesophageal Junction
Introduction
In June 2021, the EMA granted marketing authorization to pembrolizumab in combination with a platinum- and fluoropyrimidine-based chemotherapy for locally advanced unresectable or metastatic esophageal carcinoma and HER2-negative adenocarcinoma of the gastroesophageal junction in adults with tumors expressing PD-L1 (CPS ≥10). As pathologists, we will therefore be conducting immunohistological testing of both squamous cell carcinomas and adenocarcinomas (all AEG types) for PD-L1 as necessary.
Data protection and the German Drug Advertising Act (HWG) require that the professional affiliation of the portal visitors. The complete page with all contents is only available to medical personnel.
You can login with DocCheck, you QuIP-Account or Access-Code.
Login with QuIP-Account
Please enter your user name (e-mail address) and the corresponding password, which you also need for your login to the ring trial portal www.quip.eu can be used.
Login with Access-Code
Please enter your personal code, which you have already received by voucher.